Biocon Publishes Positive Phase III Clinical Data for Yesafili™, Strengthening U.S. Launch Strategy
Biocon Limited has achieved another significant milestone in its biosimilars journey with the publication of two important Phase III clinical studies validating the safety, efficacy, and immunogenicity of Yesafili™ (aflibercept-jbvf), the company’s interchangeable biosimilar to Eylea®. The research, published in the British Journal of Ophthalmology and Expert Opinion on Biological Therapy, reinforces Biocon’s scientific foundation as it prepares for the commercial launch of Yesafili™ in the United States.
The newly published studies are based on Biocon’s comprehensive Phase III INSIGHT clinical program, which evaluated MYL-1701P, now marketed as Yesafili™, in patients with Diabetic Macular Edema (DME)—one of the leading causes of vision loss among people with diabetes.
Phase III Studies Confirm Comparable Safety and Effectiveness
According to the published clinical data, Yesafili™ demonstrated outcomes comparable to the reference product across multiple clinical endpoints.
Long-Term Safety and Efficacy
Patients who continued treatment with Yesafili™ and those who switched from the reference Eylea® maintained comparable levels of:
- Safety
- Clinical efficacy
- Immunogenicity
- Visual acuity improvement
- Retinal thickness reduction
The findings remained consistent throughout the extended 20-week evaluation period, highlighting the biosimilar’s long-term treatment reliability.
Consistent Results Across Diverse Patient Groups
The studies also showed that Yesafili™ delivered comparable clinical benefits across a broad range of patients with diabetic macular edema. Improvements in both vision and retinal anatomy closely matched those achieved with the reference biologic, supporting the biosimilar’s clinical equivalence regardless of patient subgroup.
These results further strengthen physician confidence in the product’s performance across real-world treatment populations.
Interchangeable Status Creates Competitive Advantage
Yesafili™ received approval from the U.S. Food and Drug Administration (FDA) along with an interchangeable designation in May 2024. This designation is particularly valuable because it allows pharmacists, where permitted under state laws, to substitute Yesafili™ for Eylea® without requiring prior approval from the prescribing physician.
The interchangeable status is expected to:
- Improve patient access to affordable biologic therapy
- Reduce treatment costs
- Encourage broader adoption within the U.S. ophthalmology market
- Increase competition in the anti-VEGF biosimilar segment
Given the high cost of biologic treatments for retinal diseases, interchangeable biosimilars have the potential to generate meaningful healthcare savings while maintaining clinical outcomes.
Leadership Highlights Scientific Milestone
Commenting on the publication, Shreehas Tambe, CEO and Managing Director of Biocon, described the peer-reviewed studies as an important milestone for the company’s aflibercept biosimilar program. He noted that the publications provide robust scientific validation as Biocon prepares for the upcoming U.S. commercial launch.
The publication of data in internationally respected medical journals also enhances physician confidence by providing independent, peer-reviewed evidence supporting Yesafili™’s safety and effectiveness.
Expanding Biocon’s Global Biosimilar Portfolio
Biocon has established itself as one of the world’s leading biosimilar developers, with products spanning oncology, diabetes, immunology, and ophthalmology. The addition of Yesafili™ further strengthens the company’s ophthalmology portfolio and expands its presence in the rapidly growing global biosimilars market.
As demand for affordable biologic therapies continues to rise, scientifically validated biosimilars like Yesafili™ are expected to play an increasingly important role in improving healthcare accessibility while reducing treatment costs.